Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Virginiamycin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources

Virginiamycin and broiler performance.

Two experiments were conducted with broilers to determine the effect of Virginiamycin supplementation on performance and shank pigmentation. Virginiamycin supplementation at 10 ppm resulted in significantly increased body weights in both experiments. Feed efficiency was significantly improved in Experiment 1 by the supplementation of 5 and 10 ppm Virginiamycin. In Experiment 2, 20 ppm Virginiamycin was included and resulted in no greater response than that observed at 10 ppm. Pigmentation values as measured by a reflectance colorimeter and Roche color fan favored (P less than or equal to .05) Virginiamycin supplementation in both experiments. Data indicated that when the diet was supplemented with Virginiamycin an increase in the utilization of xanthophyll resulted. Mortality was not influenced by dietary treatment.

Animals↗

Virginiamycin and laying hen performance.

Two experiments were conducted for five 28-day periods each. In Experiments 1 and 2, Hyline W-36 hens, 36 and 26 weeks of age, respectively, were used. Experiment 1 was designed to measure the effect of virginiamycin on hen performance and egg characteristics when supplementing a diet having low pigmentation potential. In Experiment 2, the diet contained 3% added fat with 0, 10, and 20 ppm virginiamycin. In Experiment 1, virginiamycin-supplemented hens showed increased (P less than or equal to .05) egg production, body weight, and improved feed efficiency. When egg production and feed efficiency were ranked by quartiles within the control and virginiamycin-supplemented groups, virginiamycin was shown to benefit only the poorer producing hens. In Experiment 2, added fat improved feed efficiency; however, the response to virginiamycin, as observed in Experiment 1, did not occur.

Animals↗

Influence of virginiamycin and dietary manganese on performance, manganese utilization, and intestinal tract weight of broilers.

An experiment was conducted with day-old Cobb feather-sexed chicks for 21 days to study the effect of virginiamycin and dietary manganese on tissue uptake of manganese and intestinal tract weight. The 2 X 2 factorial arrangement of dietary treatments included 0 or 12 ppm virginiamycin and 0 or 1000 ppm added manganese as MnSO4 X H2O. Ad libitum intake was determined with four pens of five birds fed the basal corn-soybean meal diet. To eliminate the possibility that tissue manganese concentration of virginiamycin-fed birds could be attributed to increased dietary manganese intake, chicks fed experimental diets were restricted to 90% of the previous day's intake of ad libitum-fed birds. Feed intake, average daily gain, and feed efficiency were not affected by treatments. Virginiamycin decreased (P less than .001) relative intestinal tract weight from 3.34 to 2.68 g/100 g body weight. Kidney and bone manganese increased (P less than .05) when virginiamycin was fed (14.0 vs. 15.4 ppm dry basis and 21.8 vs. 24.6 ppm ash basis, respectively), indicating that virginiamycin increased absorption of manganese.

Animals↗

Preparation and properties of derivatives of virginiamycin S.

Reduction of virginiamycin S with sodium borohydride produces allo- and normal-dihydro-virginiamycin S. Reduction of the tosylhydrazone of virginiamycin S with sodium cyanoborohydride affords deoxyvirginiamycin S. These compounds are less active than virginiamycin S. Like virginiamycin S they enhance the activity of virginiamycin M1.

Bacteria↗

Identification by gene deletion analysis of barB as a negative regulator controlling an early process of virginiamycin biosynthesis in Streptomyces virginiae.

The Streptomyces virginiae gamma-butyrolactone autoregulator virginiae butanolide is a low-molecular-weight Streptomyces hormone eliciting virginiamycin biosynthesis through its binding to the specific receptor protein, BarA. Immediately downstream of barA lies barB, the transcription of which is tightly repressed by BarA in the absence of virginiae butanolide and derepressed in its presence. Thus, BarB is next to BarA on the virginiae butanolide-BarA signaling cascade. An in-frame 279-bp deletion was introduced into the barB allele, which rendered it inactive by eliminating the majority of the coding region, including the helix-turn-helix DNA-binding motif. No significant change was observed with the Delta barB mutant with respect to the timing or amount of virginiae butanolide production, or the morphological differentiation on solid media, indicating that barB neither participates in virginiae butanolide biosynthesis nor in cytodifferentiation. In contrast, analysis of virginiamycin production in the Delta barB mutant revealed that production of both virginiamycin M(1) and virginiamycin S occurred immediately after virginiae butanolide production, 2-3 h earlier than in the wild-type strain, indicating that BarB participates in the temporal retardation of virginiamycin production after virginiae butanolide inactivates the repressor function of BarA. RT-PCR analysis of the transcription of several genes surrounding barA-barB by the Delta barB mutant indicated that BarB plays a negative regulatory role, directly or indirectly, in the transcription of barZ, vmsR, and orf5 located upstream of barB.

Amino Acid Sequence↗

Action of erythromycin and virginiamycin S on polypeptide synthesis in cell-free systems.

Erythromycin (a 14-membered macrolide) and virginiamycin S (a type B synergimycin) block protein biosynthesis in bacteria, but are virtually inactive on poly(U)-directed poly(Phe) synthesis. We have recently shown, however, that these antibiotics inhibit the in vitro polypeptide synthesis directed by synthetic copolymers: this effect is analyzed further in the present work. We were unable to find any consistent alteration produced by these antibiotics on coupled and uncoupled EF-G- and EF-Tu-dependent GTPases, on the EF-Tu-directed binding of aminoacyl-tRNA to ribosomes, and on the EF-G- and GTP-mediated translocation of peptidyl-tRNA bound to poly(U,C).ribosome complexes. With these complexes, the peptidyl transfer reaction, as measured by peptidylpuromycin synthesis, was 10-30% inhibited by virginiamycin S and erythromycin. A direct relationship between the virginiamycin S- and erythromycin-promoted inhibition of poly(A,C)-directed polypeptide synthesis, on the one hand, and the EF-G concentration and the rate of the polymerization reaction, on the other hand, was observed, in agreement with a postulated reversible inhibitor action of these antibiotics. The increased inhibitory activity, which was observed during the first 4-6 rounds of elongation, in the presence of virginiamycin S or erythromycin, was suggestive of a specific action of these antibiotics on the correct positioning of peptidyl-tRNA at the P site. The marked stimulation of premature release of peptidyl-tRNA from poly(A,C).ribosome complexes can be referred to an altered interaction of the C-terminal aminoacyl residue of the growing peptidyl chain with the ribosome. We conclude that the action of virginiamycin S and erythromycin entails a template-dependent alteration of the interaction of peptidyl-tRNA with the donor site of peptidyltransferase, which may lead to a transient functional block of the ribosome and in some instances to a premature release of peptidyl-tRNA and termination of the elongation process.

Erythromycin↗

Action of virginiamycin M on the stability of different ribosomal complexes to ultracentrifugation.

It was previously shown that virginiamycin M produces in vivo an accumulation of pressure-sensitive (60 S) ribosomes, and in vitro an inactivation of the donor and acceptor sites of peptidyl transferase. The latter action, however, is expected to cause the accumulation in vivo of ribosome complexes carrying acylated tRNA species: such complexes are usually endowed with pressure resistance. However, present data indicate that poly(U).ribosome complexes carrying Phe-tRNA, Ac-Phe-tRNA or Ac-Phe-Phe-tRNA at either the A or the P site become pressure-sensitive after exposure to virginiamycin M in vitro. It is known also that uncoupled EF-G GTPase is stimulated by P-site-bound unacylated tRNA, not by the acylated species. Our data show, however, a stimulation of EF-G GTPase, when ribosomal complexes carrying Ac-Phe-tRNA or Ac-Phe-Phe-tRNA at the P site are incubated with virginiamycin M. The interpretation proposed to account for all these findings is that complexes carrying A- and P-site-bound aminoacyl-tRNA derivatives, which undergo a stable interaction with the peptidyl transferase, are endowed with ultracentrifugal stability, whereas complexes with unacylated tRNA (which does not interact with the enzyme) are pressure-sensitive. By inactivating the donor and acceptor sites of peptidyltransferase, virginiamycin M causes aminoacyl-tRNA.ribosome complexes to mimic tRNA.ribosome complexes in their pressure-lability and competence in EF-G GTPase stimulation. This interpretation is supported by the finding that the ribosome-promoted protection of aminoacyl-tRNA against spontaneous hydrolysis is suppressed by virginiamycin M.

Binding Sites↗

Effect of virginiamycin on feed intake, daily gains, ruminal volatile fatty acids and blood parameters in veal calves.

The effect of a peptolide antibiotic virginiamycin on the growth, rumen and blood parameters was followed in 8 milk-fed calves, 4 weeks old initially. Calves were individually housed in metabolic cages. The experiment was ended at the age of 16 weeks. Virginiamycin was supplied at 80 mg per head per day. Calves receiving virginiamycin gained 5.1% more than control calves. Feed intake per 1 kg of body weight gain was higher in control calves. Virginiamycin significantly increased molar percentage of propionate and decreased molar acetate: propionate ratio in rumen fluid. Serum iron, hematocrit and hemoglobin were significantly increased in the treated group in the last period of the trial. Virginiamycin lowered serum protein and urea and tended to decrease activity of aminotransferases.

Animals↗

A dose titration study on the effect of virginiamycin on gilt/sow and piglet performance.

Virginiamycin (VM), a compound with proven performance-promoting properties in pigs, can also be considered as sow performance enhancer. The present dose titration study investigates the long-term effects of VM on gilt/sow and litter performance. A total of 140 healthy gilts, in 35 sets of 2 + 2 siblings each, were used in this trial; gilts in each set were randomly allocated to the four treatments (35 gilts per each treatment group): VM0 = negative control, virginiamycin 0 mg/kg, VM20 = virginiamycin 20 mg/kg, VM40 = virginiamycin 40 mg/kg and VM60 = virginiamycin 60 mg/kg of feed. VM was added to the gilt/sow feed for a period starting from 6 months of age up to conception of the fourth parity, covering three complete breeding cycles (pregnancy, lactation and weaning-to-conception interval). The feed given did not contain any other antibacterial agent or performance enhancer. Piglets were given exactly the same quantity of creep feed from the fifth day onwards; it did not contain any antibacterial agent or performance enhancer. The lactation period was the same in all gilts/sows (21 days). Results indicate that VM supplementation of the feed improved gilt/sow performance by: (i) increasing (P < 0.05) the mean body weight at each farrowing, (ii) decreasing (P < 0.05) the mean weight loss from farrowing to weaning, and (iii) decreasing (P < 0.05) the mean weaning-to-conception intervals. VM supplementation of gilt/sow feed also resulted in improved litter size and litter performance in terms of: (i) a higher (P < 0.05) mean number of piglets born alive at each birth, (ii) a higher (P < 0.05) mean number of piglets weaned, (iii) a higher (P < 0.05) mean piglet body weight at each birth, and (iv) a higher (P < 0.05) mean piglet body weight at each weaning. These beneficial effects of VM were more pronounced in the VM40 group.

Animals↗

A dose titration study on the effect of virginiamycin on specific blood parameters and milk quality in the sow.

The present study investigates the changes in blood cholesterol and total lipids concentrations, as well as changes in milk fat, protein, lactose and total solids content of sows after the long-term administration of virginiamycin (VM) in the feed. Seventy-two (72) healthy Dalland gilts, in 18 groups of four (2 + 2) siblings were used in total. The gilts of each group of siblings were randomly allocated to one of the following four dietary treatments: VM0 = negative control, virginiamycin 0 mg/kg, VM20 = virginiamycin 20 mg/kg feed, VM40 = virginiamycin 40 mg/kg feed and VM60 = virginiamycin 60 mg/kg of feed. Treatments started at the age of 6 months covering three complete breeding cycles (up to the third weaning). The first eight groups of siblings (eight gilts per treatment/32 gilts in total) were used for blood sampling (blood group), while the remaining 10 groups of siblings (10 gilts per treatment/40 gilts in total) were used for milk sampling (milk group). Feeds given at insemination, pregnancy and lactation did not contain any other antibacterial or performance enhancer. The results indicate that all three levels of VM supplementation of gilt/sow feed influenced certain blood parameters by increasing (P < 0.05) both cholesterol and total lipids concentrations on the 30th and 60th day of each pregnancy, at each farrowing and at each weaning. The effect of dietary VM on these blood parameters remained constant throughout three consecutive parities. Moreover, the results indicate a beneficial effect of dietary VM on the milk quality of the sows during the third lactation by increasing (P < 0.05) (i) the mean fat content, (ii) the mean protein content, (iii) the mean lactose content and (iv) the mean total solids content. The highest (P < 0.05) levels in both blood and milk parameters were noticed at the inclusion level of 40 mg/kg of feed.

Animals↗

Macromolecule metabolism and photosynthetic functions in blue-green algae treated with virginiamycin, an inhibitor of protein synthesis.

The M component of virginiamycin inhibited growth of Plectonema boryanum under both photoautotrophic and heterotrophic conditions. Though the S component of this antibiotic had no apparent activity per se, it enhanced the inhibitory action of its partner. Cells incubated with suitable concentrations of either M or M + S stopped growing and lysed. Loss of the colony-forming capacity occurred quickly in the presence of M + S and slowly in the presence of M alone. Virginiamycin M inhibited protein synthesis in autotrophically and heterotrophically growing Plectonema. This effect was very rapid and could be reversed by removing the antibiotic. The S component did not block the incorporation of amino acids into proteins, but prevented the reversibility of the inhibitory effect of M. Virginiamycin M or S did not affect the photosynthetic oxygen development (Hill's reaction) in Plectonema. Moreover, carbon dioxide photoassimilation and formation of chlorophyll were inhibited only after an appreciable lag. Deoxyribonucleic acid synthesis was blocked virtually without delay by virginiamycin M. Since virginiamycin inhibited protein synthesis in a similar fashion in the unicellular Anacystis nidulans, as well as in the filamentous P. boryanum, the mechanism of action of this antibiotic is probably the same in all blue-green algae.

Anti-Bacterial Agents↗

Identification and in vivo functional analysis of a virginiamycin S resistance gene (varS) from Streptomyces virginiae.

BarA of Streptomyces virginiae is a specific receptor protein for virginiae butanolide (VB), one of the gamma-butyrolactone autoregulators of the Streptomyces species, and acts as a transcriptional regulator controlling both virginiamycin production and VB biosynthesis. The downstream gene barB, the transcription of which is under the tight control of the VB-BarA system, was found to be transcribed as a polycistronic mRNA with its downstream region, and DNA sequencing revealed a 1,554-bp open reading frame (ORF) beginning at 161 bp downstream of the barB termination codon. The ORF product showed high homology (68 to 73%) to drug efflux proteins having 14 transmembrane segments and was named varS (for S. virginiae antibiotic resistance). Heterologous expression of varS with S. lividans as a host resulted in virginiamycin S-specific resistance, suggesting that varS encoded a virginiamycin S-specific transport protein. Northern blot analysis indicated that the bicistronic transcript of barB-varS appeared 1 to 2 h before the onset of virginiamycin M1 and S production, at which time VB was produced, while exogenously added virginiamycin S apparently induced the monocistronic varS transcript.

4-Butyrolactone↗

Effects of dietary virginiamycin on performance and liver abscess incidence in feedlot cattle.

The effects of dietary virginiamycin level on performance and liver abscesses in feedlot cattle were evaluated in seven dose-response studies. Steers and heifers were fed finishing diets ranging in energy content from 1.34 to 1.51 Mcal of NEg/kg of DM. In all studies, virginiamycin added to the diet improved average daily gain and(or) feed conversion, with no substantial effect on dry matter intake. Pooled analyses of four studies providing virginiamycin at 11.0, 19.3, and 27.6 mg/kg of DM in the complete diet indicated that growth and feed conversion were linearly improved (P < .05); feeding 19.3 mg/kg improved these measurements by 3.0 and 3.8%, respectively. Overall incidence (score 0 vs score 1, 2, and 3) and severity (score 0, 1, and 2 vs score 3) of liver abscesses were reduced (P < .01) by feeding virginiamycin at either 19.3 or 27.6 mg/kg. Linear plateau modeling indicated that the effective dose range for virginiamycin in feedlot diets (DM basis) was 19.3 to 27.3 mg/kg for increasing average daily gain, 13.2 to 19.3 mg/kg for improving feed conversion, and 16.5 to 19.3 mg/kg for reducing liver abscess incidence.

Animals↗

Effects of fiber and virginiamycin on nutrient absorption, nutrient retention and rate of passage in growing swine.

Three balance trials, each involving 12 crossbred gilts averaging 35.2 kg body weight, were conducted to determine the effects of dietary fiber and virginiamycin on nutrient digestibility, mineral absorption and retention, and digesta rate of passage (RP). Two levels of fiber (13.5 and 20.2% neutral detergent fiber) and two levels of virginiamycin (0 and 11 ppm) were used in a 2 X 2 factorial arrangement of treatments. All diets were isonitrogenous and isocaloric. The RP was determined by observing the time required for a change in feces color after the addition of .5% chromic oxide to the diet. The high fiber diet had a faster (P less than .01) RP, which was associated with depressions (P less than .001) in the digestibility of dry matter (DM), energy (E), cell contents, neutral detergent fiber (NDF), acid detergent fiber (ADF), hemicellulose (HC), cellulose, permanganate lignin and ash. Virginiamycin supplementation slowed (P less than .004) the RP of both low and high fiber diets, but improved (P less than .05) the DM, E, NDF, ADF, HC and cellulose digestibility of the high fiber diet only. Fiber increased (P less than .06) fecal N excretion, whereas virginiamycin supplementation decreased (P less than .08) fecal N excretion. The addition of virginiamycin improved the absorption and retention of P, Ca, Mg, Cu, Fe, Zn and Mn when added to the high fiber diet, but had little or no effect when added to the low fiber diet even though absorption and retention values for most minerals were similar or slightly higher for the unsupplemented high fiber diet compared with the unsupplemented low fiber diet.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Response of growing-finishing pigs to decreasing floor space allowance and(or) virginiamycin in diet.

Five hundred forty crossbred pigs were utilized in four trials (10 replications) at two stations to determine the separate and interacting effects of decreasing floor space allowance with or without the addition of virginiamycin to the diet on performance of growing-finishing pigs. Pigs were allowed .37, .33 or .28 m2/pig during the growing phase (23 to 55 kg) and .74, .66, .56 m2/pig during the finishing phase (55 to 100 kg) and fed either a corn-soybean meal control diet or the control diet plus 11 mg of virginiamycin/kg of diet. Floor space allowances were achieved by varying pen size, so the number of pigs and feeder space per pig were constant for all pens. During the growing phase, daily gain (P less than .01) daily feed intake (P less than .05) and feed conversion ratio (P less than .05) decreased as floor space allowance decreased. During the finishing phase and for the total test period, daily gain (P less than .01) and feed conversion ratio (P less than .05) were reduced but daily feed intake was not affected (P greater than .05) by restricted floor space allowance. The addition of virginiamycin to the diet had no effect on pig performance. The virginiamycin X floor space allowance interaction was not significant, suggesting that pigs fed a diet with or without virginiamycin responded similarly to restricted floor space allowance. The data suggest that the addition of virginiamycin to the diet was ineffective in overcoming the decrease in performance of growing-finishing pigs caused by crowded conditions.

Animal Feed↗

Influence of Virginiamycin on yield of broilers fed four levels of energy.

An experiment was conducted to determine the effect of dietary Virginiamycin on processing yields of broilers fed four levels of energy. Body weights (catch, slaughter) and carcass weights (dry shell and ready-to-cook) were recorded. Shrink (holding weight loss), water uptake, shell yield, and ready-to-cook yield of the carcasses were calculated. Body weights were higher at higher energy levels and with addition of Virginiamycin to the diets. Weight loss due to shrink declined from 5.39 to 3.89% at higher dietary energy levels, but shrink was not affected by Virginiamycin. Water uptake was significantly higher for carcasses of birds fed the lowest dietary energy level (3.49%) than for carcasses of birds fed the two highest energy levels (2.89 and 3.03%); but differences among water uptake of carcasses of birds fed the three highest energy levels were not significant. Water uptake was unaffected by Virginiamycin. Increasing the dietary energy level resulted in higher ready-to-cook yields, from 61.7% yield at 2,271 kcal ME/kg to 65.4% yield at 2,953 kcal ME/kg. Yield was increased from 63.3 to 64.0% (P less than .01) by dietary Virginiamycin.

Animals↗

The response of male chicken broilers to the dietary addition of virginiamycin.

Two replicate trials, each involving 400 Arbor Acre male broiler chicks, were conducted to determine the effect of virginiamycin as a growth promoter when added to either the feed or drinking water. A control group received no growth promoter while one treatment group was provided a diet containing 11 mg of virginiamycin/kg. Another treatment group was provided drinking water containing virginiamycin in amounts calculated to ensure equivalent or one-half equivalent intake of the antibiotic. Virginiamycin supplementation had no significant (P greater than .05) effect on mortality or feed conversion ratios, regardless of the mode of administration. Body weights at 21 days of age but not at 42 days of age were significantly (P less than .05) heavier for broilers receiving virginiamycin via the drinking water. The inclusion of virginiamycin in the feed failed to improve body weights at either 21 or 42 days of age.

Animal Feed↗

[The effect of cyadox and virginiamycin on Marek's disease in chickens].

Chickens infected with highly virulent Marek's disease virus were administered in the course of 56-day fattening cyadox at a dose of 20 mg per kg feed mixture (MC group). and virginiamycin at a dose of 10 mg per kg feed mixture (MV group). The weight gains on the 56th day and dressing percentage were highest, in comparison with the control group (711.11 g and 60.62%), in the virginiamycin-treated group. An investigation into the basic chemical composition of meat revealed lower contents of dry matter and proteins in the virginiamycin-treated group (26.9% and 22.76%) if compared with the control group of chickens which were also infected with Marek's disease virus. A biometrical examination of the organs showed a statistically significant decrease in heart weight in the cyadox-treated group, increase in liver and heart weight and intestine shortening in the virginiamycin-treated group, in comparison with the control group. Pathologico-anatomical changes typical of Marek's disease were recorded in a randomly selected number of chickens in 33.3% in the control group, in 28.5% in the cyadox-treated group and in 50.0% in the virginiamycin-treated group.

Animals↗